S&P Futures
2,418.00
-2.50 (-0.10%)Dow Futures
21,283.00
-8.00 (-0.04%)
| Previous Close | 87.63 |
| Open | 87.14 |
| Bid | 71.12 x 1000 |
| Ask | 71.74 x 44000 |
| Day's Range | 86.16 - 87.21 |
| 52 Week Range | 66.72 - 92.97 |
| Volume | 501,106 |
| Avg. Volume | 2,419,940 |
| Market Cap | 105.42B |
| Beta | 0.73 |
| PE Ratio (TTM) | 11.93 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 3.30 (3.35%) |
| Ex-Dividend Date | 2017-05-16 |
| 1y Target Est | N/A |
- Barrons.com•19 hours ago
Regeneron: The More the Merrier?
Last week we noted that when a stock has a big rally, analysts are forced to either cut their rating or raise their target price. Today, Leerink's Geoffrey Porges and Bradley Canino raise their Regeneron target to $573 from $483: After lots of news in the last week, and a major shift in value, and expectations, we are updating our Regeneron model to incorporate higher expected sales of Dupixent (including adult atopic dermatitis, pediatric atopic dermatitis, high eosinophil and non-eosinophilic asthma), lower expected sales of Eylea (accounting for some erosion by RTH258 starting in 2019), and including for the first time revenue from REGN2810, which is the company’s joint (with Sanofi (SNY)) PD-1 antibody.
- Zacks•19 hours ago
Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU
Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.
- The Wall Street Journal•yesterday
[$$] Third Point Move Could Lead to Nestlé-L’Oréal Decoupling
Is Nestlé’s stake in L’Oréal in play? Daniel Loeb is pushing the Swiss food giant to sell its $27.4 billion stake in the French cosmetics firm.
